RNAi has been demonstrated to be more effective than other gene targeting approaches such as anti-sense RNA and anti-sense oligonucleotides [51], [52], and studies utilizing direct intravenous application of siRNA to target genes such as FAS for the treatment of fulminant hepatitis [53] support the usefulness of direct application of siRNA to control the expression of target proteins in cancer and other diseases. Here, FAS is linked to Fulminant hepatitis.